How can we make novel treatments of glomerular diseases available for children as early and safely as possible?
Author:
Open Access
- 22 September 2025
- journal article
- editorial
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (4) , 907-911
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Comparing adolescent glomerular disease clinical outcomes to the clinical outcomes in childhood, young adult, and adult-onset glomerular disease in the CureGN databasePediatric Nephrology, 2024
- C3 glomerulopathy in children: a European longitudinal study evaluating outcomePediatric Nephrology, 2024
- IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritisPediatric Nephrology, 2024
- Outcome of rituximab treatment in children with non-dialysis-dependent anti-GBM diseasePediatric Nephrology, 2024
- Efficacy and safety of belimumab therapy for patients with lupus nephritis: A meta‐analysis and a propensity score‐matched case–control studyImmunity, Inflammation and Disease, 2023
- IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndromePediatric Nephrology, 2022
- IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndromePediatric Nephrology, 2020
- Brief Report: Rituximab for the Treatment of Adult‐Onset IgA Vasculitis (Henoch‐Schönlein)Arthritis & Rheumatology, 2017
- Membranous nephropathy in children: clinical presentation and therapeutic approachPediatric Nephrology, 2009
- Differences in long‐term disease activity and treatment of adult patients with childhood‐ and adult‐onset systemic lupus erythematosusArthritis Care & Research, 2008